PDCD1 and neoplasm: ICIs release the immune brake response and inhibit tumor immune escape effectively by targeting lymphocyte activation gene‐3 (LAG3), cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4), programmed cell death 1 (PD‐1)/programmed cell death ligand‐1 (PD‐L1), and other targets.9, 10, 11